These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 35775133)

  • 1. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
    Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
    Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
    Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
    J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
    Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
    J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
    Warden BA; Duell PB
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
    Scheen AJ; Wallemacq C; Lancellotti P
    Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
    Sinning D; Landmesser U
    Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
    Wright RS; Raal FJ; Koenig W; Landmesser U; Leiter LA; Vikarunnessa S; Lesogor A; Maheux P; Talloczy Z; Zang X; Schwartz GG; Ray KK
    Cardiovasc Res; 2024 Oct; 120(12):1400-1410. PubMed ID: 38753448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
    Smith KW; White CM
    J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
    Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First clinical experiences with inclisiran in a real-world setting.
    Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
    J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on inclisiran for the treatment of elevated LDL cholesterol.
    Barkas F; Ray K
    Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
    Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
    S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
    Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
    Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.